Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 16/20 | 0.64 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20717712 | 1.00 | PIK3CD (0.64) | PIK3CDPIK3R1PIK3CGPIK3CBALDH1A1 | |
| SCHEMBL13161373 | 0.89 | PIK3CD (0.60) | PIK3CDPIK3R1PIK3CGPIK3CBALDH1A1 | |
| SCHEMBL15812924 | 0.87 | PIK3CD (0.60) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL15812927 | 0.87 | PIK3CD (0.60) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL16583419 | 0.86 | PIK3CD (0.60) | PIK3CDPIK3R1PIK3CGPIK3CBALDH1A1 | |
| SCHEMBL754924 | 0.86 | PIK3CD (0.60) | PIK3CDPIK3R1PIK3CGPIK3CBALDH1A1 | |
| SCHEMBL13007621 | 0.85 | PIK3CD (0.58) | PIK3CDPIK3R1PIK3CGPIK3CBALDH1A1 | |
| SCHEMBL28436002 | 0.82 | PIK3CD (0.53) | PIK3CDPIK3R1PIK3CGPIK3CBALDH1A1 | |
| SCHEMBL28436003 | 0.82 | PIK3CD (0.53) | PIK3CDPIK3R1PIK3CGPIK3CBALDH1A1 | |
| SCHEMBL20703745 | 0.82 | PIK3CD (0.52) | PIK3CDPIK3R1PIK3CGPIK3CBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459306-B2 | Compounds, compositions, and methods for treating T-cell acute lymphoblastic leukemia | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-10-04 | — | — | US | disclosed |
| CN-111386264-A | Compounds, compositions and methods for treating T-cell acute lymphoblastic leukemia | 纽约市哥伦比亚大学理事会 | 2020-07-07 | — | — | CN | disclosed |
| US-10695349-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| EP-3661924-A1 | COMPOUNDS, COMPOSITIONALS, AND METHODS FOR TREATING T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | The Trustees of Columbia University in the City of New York (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20200165211-A1 | Compounds, Compositions, and Methods for Treating T-Cell Acute Lymphoblastic Leukemia | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-05-28 | — | — | US | disclosed |
| US-20200061062-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2020-02-27 | — | — | US | disclosed |
| US-10398695-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2019-09-03 | — | — | US | disclosed |
| WO-2019028055-A1 | COMPOUNDS, COMPOSITIONALS, AND METHODS FOR TREATING T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | THE TRUSTEES OF COLUMBIA UNIVERISTY IN THE CITY OF NEW YORK (US) | 2019-02-07 | — | — | WO | disclosed |
| US-10010550-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2018-07-03 | — | — | US | disclosed |
| US-10010550-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2018-07-03 | — | — | US | disclosed |
| US-8492389-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2013-07-23 | — | — | US | disclosed |
| US-20120172591-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120135994-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135994-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2012-05-31 | — | — | US | disclosed |
| US-8138195-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138195-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2012-03-20 | — | — | US | disclosed |
| EP-1438052-B1 | QUINAZOLIN-4-ONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20100168139-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-07-01 | — | — | US | disclosed |
| US-20100152211-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-20100152211-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152211-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885PIK3R1 12/4885PIK3CG 3/4885 |
| US-20100168139-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885PIK3R1 12/4885PIK3CG 3/4885 |
| US-20120135994-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885PIK3R1 12/4885PIK3CG 3/4885 |
| US-11459306-B2 | Compounds, compositions, and methods for treating T-cell acute lymphoblastic leukemia | BCL9, BCL3, MCL1 | PIK3CD 15/4885PIK3R1 28/4885PIK3CG 11/4885 |
| US-20120172591-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885PIK3R1 12/4885PIK3CG 3/4885 |
| US-20200061062-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885PIK3R1 12/4885PIK3CG 3/4885 |
| US-20200165211-A1 | Compounds, Compositions, and Methods for Treating T-Cell Acute Lymphoblastic Leukemia | BCL9, BCL3, MCL1 | PIK3CD 15/4885PIK3R1 28/4885PIK3CG 11/4885 |
| US-10695349-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885PIK3R1 12/4885PIK3CG 3/4885 |
| US-10010550-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885PIK3R1 12/4885PIK3CG 3/4885 |
| US-10398695-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885PIK3R1 12/4885PIK3CG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.